The short version of alpha-MSH analog fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-11-01 and is reviewed periodically as new material appears.
Published research on the compound remains limited. Much of the human data comes from small, early-stage studies rather than large controlled trials, and several questions about effects and variability between individuals remain open. Investigators have examined receptor activity, pigment pathways, and related physiological responses in laboratory and animal models. Findings from those models do not automatically translate to human outcomes. Reviews frequently note the scarcity of rigorous clinical evidence and call for better-characterized study material.
Because the substance circulates mainly through informal markets, verification is a recurring theme in technical discussion. Independent analyses have found that labeled content and actual content can diverge, and that purity varies between samples. Analytical laboratories use reversed-phase chromatography to separate components and mass spectrometry to confirm identity. Isotope-labeled internal standards improve quantification in complex matrices. Such methods describe what a sample contains but say nothing about its sterility, lawful status, or suitability for any use. Open questions remain about how consistently testing is applied across the supply chain.
Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | No marketing authorization in major jurisdictions |
| Scheduling example | Prescription-only supply in some countries | Handled as an unlicensed medicine where restricted |
| Sports classification | Prohibited peptide | Appears on anti-doping prohibited lists |
| Reported presentation | Lyophilized vial | Nominal content varies between vendors |
| Detection approach | Liquid chromatography–tandem mass spectrometry | Used in anti-doping and forensic testing |
Regulatory treatment varies by country. In the United States the peptide is not approved as a medicine, and products offered for human use may be treated as unapproved new drugs; some states also restrict sale. Australia, the United Kingdom, and European Union member states apply comparable restrictions to unapproved peptide products. Border agencies have seized shipments labelled as research chemicals. Classification may change over time, and the legal position for personal importation is not clearly settled in most published guidance.
Lyophilised melanotan-2 is supplied as a solid, which is more stable than a solution. The material is hygroscopic, so weighing is done quickly, in low humidity, with the container kept sealed. Reconstitution usually uses water for injection or bacteriostatic water, added down the wall of the vial to limit foaming. A reconstituted solution is held at 2 to 8 °C and kept away from light. Repeated freezing and thawing of the same vial is avoided because ice crystal formation and concentration effects degrade the peptide.
Research interest has centred on photoprotection and pigmentation, with a smaller body of work on appetite and sexual function. Published human data remain limited to small, frequently uncontrolled studies, and the compound has never received marketing approval from a national medicines regulator. Most laboratory work treats it as a pharmacological tool for probing melanocortin signalling in cell culture or animal models. Whether pigmentation changes observed in people translate into measurable protection against ultraviolet-induced DNA damage remains an open question.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, the naturally occurring peptide involved in pigmentation signalling. Its sequence is conventionally written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a lactam bridge joining the aspartate side chain to the lysine side chain. The empirical formula is C50H69N15O9 and the monoisotopic mass lies near 1023.5 daltons. N-terminal acetylation and the D-configured phenylalanine both increase resistance to enzymatic breakdown compared with the parent hormone.
Pharmacologically, melanotan-2 behaves as a non-selective agonist across the melanocortin receptor family. Binding at MC1R on dermal melanocytes promotes eumelanin synthesis, which underlies the tanning response described in early human work. Activity at the centrally expressed MC4R receptor is associated with reported effects on appetite and erectile function. Because the peptide does not discriminate strongly among receptor subtypes, attributing any single observed effect to one receptor pathway is generally not possible without selective antagonists or receptor knockout models.
A protecting group or protective group is introduced into a molecule by chemical modification of a functional group to obtain chemoselectivity in a subsequent chemical reaction. It plays an important role in multistep organic synthesis. In many preparations of delicate organic compounds, specific parts of the molecules cannot survive the required reagents or chemical environments. These parts (functional groups) must be protected. For example, lithium aluminium hydride is a highly reactive reagent that usefully reduces esters to alcohols. It always reacts with carbonyl groups, and cannot be discouraged by any means. When an ester must be reduced in the presence of a carbonyl, hydride attack on the carbonyl must be prevented. One way to do so converts the carbonyl into an acetal, which does not react with hydrides. The acetal is then called a protecting group for the carbonyl. After the hydride step is complete, aqueous acid removes the acetal, restoring the carbonyl. This step is called deprotection. Protecting groups are more common in small-scale laboratory work and initial development than in industrial production because they add additional steps and material costs. However, compounds with repetitive functional groups – generally, biomolecules like peptides, oligosaccharides or nucleotides – may require protecting groups to order their assembly. Also, cheap chiral protecting groups may often shorten an enantioselective synthesis (e.g. shikimic acid for oseltamivir). As a rule, the introduction of a protecting group is straightforward.
Polymer concentration affects fiber properties: an increase in polymer concentration decreases porosity and increases mechanical properties such as tensile strength. Solvent properties influence morphology of the scaffolds. After gelation, gel is placed in distilled water for solvent exchange. Afterwards, the gel is removed from the water and goes through freezing and freeze-drying. It is then stored in a desiccator until characterization.
=== Pharmacodynamics === Tapentadol is a synthetic opioid with a dual mechanism of action: it acts as a full agonist of the μ-opioid receptor (MOR) and as a norepinephrine reuptake inhibitor (NRI). This unique pharmacological profile allows it to treat both nociceptive and neuropathic pain, and it is theorised that the effects on norepinephrine are a substantial benefit for people taking it. Tapentadol does not affect serotonin, unlike tramadol, which prevents the reuptake of serotonin and norepinephrine, similarly to certain antidepressants known as serotonin–norepinephrine reuptake inhibitors (SNRIs), such as desvenlafaxine and duloxetine. Tapentadol exhibits high binding selectivity and affinity for MOR, which is the principal target of the endogenous neuropeptide β-endorphin. It has significantly lower affinity for the δ-opioid receptor (DOR), κ-opioid receptor (KOR) and M1 as an antimuscarinic effect. MOR binding sites are distributed throughout the human brain, with higher densities in regions such as the amygdala, hypothalamus, thalamus, nucleus caudatus, putamen, and select cortical areas. Opioids like tapentadol are believed to mediate analgesia primarily through MOR activation in the midbrain periaqueductal gray (PAG) and rostral ventromedial medulla (RVM), thereby inhibiting ascending pain pathways. MOR activation in the intestine contributes to common opioid-related side effects such as constipation. As noted, tapentadol is structurally similar to tramadol, and both drugs utilize a dual mechanism involving the opioid and norepinephrine systems.
For non-small cell lung cancer, pembrolizumab is used in combination with chemotherapy (for all PD-L1, a PD-1 receptor ligand, levels) or by itself as a first-line treatment if the cancer expresses (≥ 1%) PD-L1 and the cancer has no mutations in EGFR or in ALK; if chemotherapy has already been administered, then pembrolizumab can be used as a second-line treatment, but if the cancer has EGFR or ALK mutations, agents targeting those mutations should be used first. Assessment of PD-L1 expression must be conducted with a validated and approved companion diagnostic.
==== Corneal Allogenic Intrastromal Ring Segments (CAIRS) ==== Corneal Allogenic Intrastromal Ring Segments Keratoplasty (CAIRS Keratoplasty) represent an innovative surgical approach for the management of keratoconus, utilizing donor corneal tissue as biocompatible implants to reshape the ectatic cornea and improve visual acuity. CAIRS is a corneal transplant and due to its success rate, efficacy, safety profile and use of biologic tissue, it been recognised as such by funding bodies in Australia, the United Kingdom, Brazil, Japan, the Netherlands, Germany and numerous other countries. Unlike traditional synthetic intrastromal corneal ring segments (ICRS), which are typically made from polymethyl methacrylate (PMMA), CAIRS keratoplasty employs preserved allogeneic donor cornea to minimize risks such as extrusion, infection, or foreign body reactions associated with non-biological materials. The technique was developed by Soosan Jacob, who first described CAIRS in 2018 in a prospective interventional case series published in the Journal of Refractive Surgery. In this study, 24 eyes of 20 patients with keratoconus (grades 2–4) underwent CAIRS implantation combined with accelerated corneal collagen cross-linking (CXL). The procedure involved femtosecond laser-assisted creation of intrastromal tunnels followed by insertion of custom-cut allogeneic segments. Key outcomes included significant improvements in uncorrected distance visual acuity (UDVA) of 2.79 ± 2.65 lines and corrected distance visual acuity (CDVA) of 1.29 ± 1.33.
Sources: en.wikipedia.org
Small interfering RNA (siRNA), sometimes known as short interfering RNA or silencing RNA, is a class of double-stranded non-coding RNA molecules, typically 20–24 base pairs in length, similar to microRNA (miRNA), and operating within the RNA interference (RNAi) pathway. It interferes with the expression of specific genes with complementary nucleotide sequences by degrading messenger RNA (mRNA) after transcription, preventing translation. It was discovered in 1998 by Andrew Fire at the Carnegie Institution for Science in Washington, D.C. and Craig Mello at the University of Massachusetts in Worcester.
Tight junctions are a formed by pairs of trans-membrane proteins that form a seal to prevent water or solutes from leaking between cells. Adherens junctions allow the cytoskeletal microfilaments of adjacent cells to interact with one another. Desmosomes allow cells to form strong attachments to one another by connecting cadherins and intermediate filaments. Hemidesmosomes resemble desmosomes but mediate cellular attachment to extracellular matrix. They use integrins instead of cadherins. Gap junctions connect the cytoplasm of adjacent cells and are made up of proteins called connexins (six of which come together to make a connexion).
With the new season of the J.League commencing in March 1995, Wenger set about assembling his squad and backroom staff. He hired former Valenciennes manager Boro Primorac, whom he had befriended during the match-fixing scandal, as his assistant. Alexandre Torres joined Nagoya after Wenger identified the defender by watching Brazilian football on the television, and the manager brought in Franck Durix and his former player Passi. Nagoya finished bottom of the J.League the season before Wenger's arrival, and continued their poor form into the following campaign, losing several matches in a row. In response to the situation, Wenger altered his managerial style, becoming less amicable with his players and openly questioning their desire. To boost morale, he took his squad to Versailles for their mid-season break, where they went through a rigorous, but creative, training regime. Players were expected to make decisions for themselves on the pitch, instead of relying on the manager; Wenger was reported to have shouted to his players "Don't look at me to ask me what to do with the ball!" and "Decide for yourself! Why don't you think it out?" One player who greatly benefited from Wenger's guidance was Dragan Stojković, a midfielder whose disciplinary record improved considerably. Wenger's methods had the desired effect – Nagoya won 17 of their following 27 games to finish runners-up in 1995. He shortly received the J. League Manager of the Year award for 1995, while Stojković claimed the player's honour.
In the first step of nixtamalization, kernels of dried maize are cooked in an alkaline solution at or near the mixture's boiling point. After cooking, the maize is steeped in the cooking liquid for a period. The length of time for which the maize is boiled and soaked varies according to local traditions and the type of food being prepared, with cooking times ranging from a few minutes to an hour, and soaking times from a few minutes to about a day. During cooking and soaking, a number of chemical changes take place in the grains of maize. Because plant cell wall components, including hemicellulose and pectin, are highly soluble in alkaline solutions, the kernels soften and their pericarps (hulls) loosen. The grain hydrates and absorbs calcium or potassium (depending on the alkali used) from the cooking solution. Starches swell and gelatinize, and some starches disperse into the liquid. Certain chemicals from the germ are released that allow the cooked grains to be ground more easily, yet make dough made from the grains less likely to tear and break down. Cooking changes the grain's protein matrix, which makes proteins and nutrients from the endosperm of the kernel more available to the human body.
In 1957, Berni Alder and Thomas Wainwright used an IBM 704 computer to simulate perfectly elastic collisions between hard spheres. In 1960, in perhaps the first realistic simulation of matter, J.B. Gibson et al. simulated radiation damage of solid copper by using a Born–Mayer type of repulsive interaction along with a cohesive surface force. In 1964, Aneesur Rahman published simulations of liquid argon that used a Lennard-Jones potential; calculations of system properties, such as the coefficient of self-diffusion, compared well with experimental data. Today, the Lennard-Jones potential is still one of the most frequently used intermolecular potentials. It is used for describing simple substances (a.k.a. Lennard-Jonesium) for conceptual and model studies and as a building block in many force fields of real substances.
Sources: en.wikipedia.org
He created the library's first Young Readers Center in the Jefferson Building in 2009, and the first large-scale summer intern (Junior Fellows) program for university students in 1991. Under Billington, the library sponsored the Gateway to Knowledge in 2010 to 2011, a mobile exhibition to ninety sites, covering all states east of the Mississippi, in a specially designed eighteen-wheel truck. This increased public access to library collections off-site, particularly for rural populations, and helped raise awareness of what was also available online. Billington raised more than half a billion dollars of private support to supplement Congressional appropriations for library collections, programs, and digital outreach. These private funds helped the library to continue its growth and outreach in the face of a 30% decrease in staffing, caused mainly by legislative appropriations cutbacks. He created the library's first development office for private fundraising in 1987. In 1990, he established the James Madison Council, the library's first national private sector donor-support group. In 1987, Billington also asked the Government Accountability Office (GAO) to conduct the first library-wide audit. He created the first Office of the Inspector General at the library to provide regular, independent reviews of library operations. This precedent has resulted in regular annual financial audits at the library; it has received unmodified ("clean") opinions from 1995 onward.
=== Gastrointestinal decontamination === In adults, the initial treatment for paracetamol overdose is gastrointestinal decontamination. Paracetamol absorption from the gastrointestinal tract is complete within two hours under normal circumstances, so decontamination is most helpful if performed within this timeframe. Gastric lavage, better known as stomach pumping, may be considered if the amount ingested is potentially life-threatening and the procedure can be performed within 60 minutes of ingestion. Administration of activated charcoal is the most common gastrointestinal decontamination procedure as it efficiently adsorbs paracetamol, thereby reducing its gastrointestinal absorption. Administering activated charcoal also poses less risk of aspiration than gastric lavage. It appears that the most benefit from activated charcoal is gained if it is given within 30 minutes to two hours of ingestion. Administering activated charcoal later than 2 hours can be considered in patients that may have delayed gastric emptying due to co-ingested drugs or following ingestion of sustained- or delayed-release paracetamol preparations. Activated charcoal should also be administered if co-ingested drugs warrant decontamination. There was reluctance to give activated charcoal in paracetamol overdose, because of the concern that it may also absorb the oral antidote acetylcysteine. Studies have shown that 39% less acetylcysteine is absorbed into the body when they are administered together.
These are required for thymidylate and purine production, which are both essential for DNA synthesis and cell division. Pemetrexed is another anti-metabolite that affects purine and pyrimidine production, and therefore also inhibits DNA synthesis. It primarily inhibits the enzyme thymidylate synthase, but also has effects on DHFR, aminoimidazole carboxamide ribonucleotide formyltransferase and glycinamide ribonucleotide formyltransferase. The fluoropyrimidines include fluorouracil and capecitabine. Fluorouracil is a nucleobase analogue that is metabolised in cells to form at least two active products; 5-fluourouridine monophosphate (FUMP) and 5-fluoro-2'-deoxyuridine 5'-phosphate (fdUMP). FUMP becomes incorporated into RNA and fdUMP inhibits the enzyme thymidylate synthase; both of which lead to cell death. Capecitabine is a prodrug of 5-fluorouracil that is broken down in cells to produce the active drug. The deoxynucleoside analogues include cytarabine, gemcitabine, decitabine, azacitidine, fludarabine, nelarabine, cladribine, clofarabine, and pentostatin. The thiopurines include thioguanine and mercaptopurine.
=== Pressure reduction === Pressure must be removed from high risk body areas by frequent changes in position in bed or chair, including turning side to side. Chair cushions and air mattresses should be used for immobile patients. Heels should be off of the bed.
== Preservatives == Frozen products do not require any added preservatives because microorganisms do not grow when the temperature of the food is below −9.5 °C (15 °F), which is sufficient on its own in preventing food spoilage. Long-term preservation of food may call for food storage at even lower temperatures. Carboxymethylcellulose (CMC), a tasteless and odorless stabilizer, is typically added to frozen food because it does not adulterate the quality of the product.
Sources: en.wikipedia.org
Only a small number of early-stage human studies have been reported, and most were limited in size and duration. No large late-stage program has established a general efficacy or safety profile. The evidence base is therefore thin compared with approved medicines.
The peptide is listed as prohibited in competitive sport, so laboratories develop detection methods and monitor for its presence. Its appearance in enforcement reports reflects that classification rather than any approved athletic use. Analytical work in this area focuses on identifying the molecule and its breakdown products in biological samples.
Chromatographic separation combined with mass spectrometry identifies the peptide and estimates its amount in a sample. Testing can confirm whether the expected molecule is present and at what concentration. It cannot establish how a product was manufactured or whether it meets any purity standard.
No regulator in a major market has approved it for human use. It appears in research settings and in products marketed outside pharmacy channels. Legal status for personal possession varies by country.